Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B6e8bafee505e9366e3018230b45904c6> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B6e8bafee505e9366e3018230b45904c6 NCIT_P378 "NCI" @default.
- B6e8bafee505e9366e3018230b45904c6 type Axiom @default.
- B6e8bafee505e9366e3018230b45904c6 annotatedProperty IAO_0000115 @default.
- B6e8bafee505e9366e3018230b45904c6 annotatedSource NCIT_C201236 @default.
- B6e8bafee505e9366e3018230b45904c6 annotatedTarget "Fc-engineered bispecific monoclonal antibody targeting both immune checkpoint regulatory proteins human programmed death-ligand 1 (PD-L1; CD274) and 2 (PD-L2; CD273), with potential immune checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-L1/PD-L2 bispecific antibody IMGS-001 simultaneously targets and binds to PD-L1 and PD-L2 expressed on tumor cells, immunosuppressive stromal cells and endothelial cells. PD-L1 and PD-L2 binding by IMGS-001 prevents both PD-L1 and PD-L2 from binding to and activating their receptor programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates PD-1-mediated signaling in T-cells and PD-1-mediated T-cell inhibition. This activates cytotoxic T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. In addition, IMGS-001 induces antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thereby killing PD-L1 and PD-L2-expressing cells in the tumor microenvironment (TME), and further abrogating the immunosuppressive nature of the TME. PD-L1 and PD-L2 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion." @default.